Age-related Macular Degeneration Market
完整報告名稱與涵蓋範圍
Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Wet AMD, Dry AMD), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, And Segment Forecasts, 2026 - 2033
報告摘要
Age-related Macular Degeneration Market Summary
The global age-related macular degeneration market size was valued at USD 11.6 billion in 2025 and is projected to grow from USD 12.5 billion in 2026 to USD 22.7 billion by 2033, at a CAGR of 9.0% from 2026 to 2033. The market in North America dominated with a revenue share of 53.9% in 2025. The market is driven by the increasing burden of the aging population, as AMD remains one of the leading causes of irreversible vision loss among older adults.
The market is supported by growing disease awareness, improvements in retinal imaging technologies such as optical coherence tomography (OCT), and broader access to specialist ophthalmology services, enabling earlier diagnosis and timely treatment. Anti-vascular endothelial growth factor (anti-VEGF) therapies remain the standard of care for neovascular (wet) AMD, while the introduction of complement pathway inhibitors has expanded treatment options for geographic atrophy in dry AMD. Ongoing research in sustained-release drug delivery systems, gene therapies, and novel biologics is strengthening the development pipeline and addressing the need to reduce treatment burden. At the same time, increasing healthcare expenditure, expanding retinal care infrastructure in developing countries, and the growing involvement of pharmaceutical and biotechnology companies in ophthalmology are supporting steady market growth across both developed and emerging regions.
Global Age-related Macular Degeneration Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Age-related macular degeneration market report based on product, disease, distribution channel, and region:
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Eylea
• Lucentis
• Beovu
• Others
• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Wet AMD
• Dry AMD
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait
授權報價
| Single User License | $5,950 USD |
| Enterprise License | $6,950 USD |
| Corporate User License | $8,950 USD |
目錄 Table of Contents
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Age-related Macular Degeneration Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Age-related Macular Degeneration Market: Product Business Analysis
4.1. Product Market Share, 2025 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Billion)
4.4. Eylea
4.4.1. Eylea Market, 2021 - 2033 (USD Billion)
4.5. Lucentis
4.5.1. Lucentis Market, 2021 - 2033 (USD Billion)
4.6. Beovu
4.6.1. Beovu Market, 2021 - 2033 (USD Billion)
4.7. Others
4.7.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. Age-related Macular Degeneration Market: Disease Business Analysis
5.1. Disease Market Share, 2025 & 2033
5.2. Disease Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Billion)
5.4. Wet AMD
5.4.1. Wet AMD Market, 2021 - 2033 (USD Billion)
5.5. Dry AMD
5.5.1. Dry AMD Market, 2021 - 2033 (USD Billion)
Chapter 6. Age-related Macular Degeneration Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2025 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
6.4. Hospital Pharmacy
6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
6.5. Retail Pharmacy
6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Billion)
6.6. Online Pharmacy
6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Billion)
Chapter 7. Age-related Macular Degeneration Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2025 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Age-related Macular Degeneration Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. Canada Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5. Europe
7.5.1. Europe Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. UK Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Target Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Target Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Target Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Target Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6. Asia Pacific
7.6.1. Asia Pacific Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Target Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7. Latin America
7.7.1. Latin America Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Target Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Brazil Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. Argentina Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Target Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Target Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Target Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Target Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Novartis AG
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Bayer AG
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Pfizer Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. F. Hoffmann-La Roche Ltd.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Bausch Health Companies Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Regeneron Pharmaceuticals Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Amgen Inc.
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Biogen
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Samsung Bioepis
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
圖表清單 List of Tables & Figures
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global Age-related macular degeneration market, by region, 2021 - 2033 (USD Billion)
Table 4. Global Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 5. Global Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 6. Global Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 7. North America Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
Table 8. North America Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 9. North America Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 10. North America Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 11. U.S. Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 12. U.S. Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 13. U.S. Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 14. Canada Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 15. Canada Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 16. Canada Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 17. Mexico Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 18. Mexico Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 19. Mexico Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 20. Europe Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
Table 21. Europe Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 22. Europe Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 23. Europe Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 24. UK Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 25. UK Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 26. UK Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 27. Germany Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 28. Germany Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 29. Germany Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 30. France Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 31. France Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 32. France Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 33. Italy Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 34. Italy Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 35. Italy Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 36. Spain Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 37. Spain Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 38. Spain Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 39. Norway Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 40. Norway Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 41. Norway Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 42. Denmark Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 43. Denmark Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 44. Denmark Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 45. Sweden Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 46. Sweden Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 47. Sweden Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 48. Asia Pacific Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
Table 49. Asia Pacific Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 50. Asia Pacific Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 51. Asia Pacific Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 52. Japan Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 53. Japan Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 54. Japan Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 55. China Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 56. China Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 57. China Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 58. India Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 59. India Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 60. India Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 61. Australia Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 62. Australia Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 63. Australia Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 64. South Korea Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 65. South Korea Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 66. South Korea Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 67. Thailand Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 68. Thailand Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 69. Thailand Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 70. Latin America Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
Table 71. Latin America Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 72. Latin America Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 73. Latin America Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 74. Brazil Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 75. Brazil Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 76. Brazil Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 77. Argentina Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 78. Argentina Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 79. Argentina Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 80. Middle East & Africa Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
Table 81. Middle East & Africa Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 82. Middle East & Africa Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 83. Middle East & Africa Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 84. South Africa Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 85. South Africa Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 86. South Africa Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 87. Saudi Arabia Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 88. Saudi Arabia Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 89. Saudi Arabia Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 90. UAE Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 91. UAE Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 92. UAE Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
Table 93. Kuwait Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
Table 94. Kuwait Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
Table 95. Kuwait Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
List of Figures
Fig. 1 Age-related macular degeneration market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape
Fig. 10 Age-related macular degeneration market dynamics
Fig. 11 Age-related macular degeneration market: Porter’s five forces analysis
Fig. 12 Age-related macular degeneration market: PESTLE analysis
Fig. 13 Product market, 2021 - 2033 (USD Billion)
Fig. 14 Eylea market, 2021 - 2033 (USD Billion)
Fig. 15 Lucentis market, 2021 - 2033 (USD Billion)
Fig. 16 Beovu market, 2021 - 2033 (USD Billion)
Fig. 17 Others market, 2021 - 2033 (USD Billion)
Fig. 18 Disease market, 2021 - 2033 (USD Billion)
Fig. 19 Wet AMD market, 2021 - 2033 (USD Billion)
Fig. 20 Dry AMD market, 2021 - 2033 (USD Billion)
Fig. 21 Distribution channel market, 2021 - 2033 (USD Billion)
Fig. 22 Hospital Pharmacy market, 2021 - 2033 (USD Billion)
Fig. 23 Retail Pharmacy market, 2021 - 2033 (USD Billion)
Fig. 24 Online pharmacy market, 2021 - 2033 (USD Billion)
Fig. 25 Age-related macular degeneration market revenue, by region
Fig. 26 Regional marketplace: Key takeaways
Fig. 27 North America Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 28 U.S. country dynamics
Fig. 29 U.S. Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 30 Canada country dynamics
Fig. 31 Canada Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 32 Mexico country dynamics
Fig. 33 Mexico Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 34 Europe Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 35 UK country dynamics
Fig. 36 UK Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 37 Germany country dynamics
Fig. 38 Germany Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 39 France country dynamics
Fig. 40 France Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 41 Italy country dynamics
Fig. 42 Italy Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 43 Spain country dynamics
Fig. 44 Spain Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 45 Norway country dynamics
Fig. 46 Norway Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 47 Sweden country dynamics
Fig. 48 Sweden Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 49 Denmark country dynamics
Fig. 50 Denmark Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 51 Asia Pacific Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 52 Japan country dynamics
Fig. 53 Japan Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 54 China country dynamics
Fig. 55 China Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 56 India country dynamics
Fig. 57 India Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 58 Australia country dynamics
Fig. 59 Australia Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 60 South Korea country dynamics
Fig. 61 South Korea Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 62 Thailand country dynamics
Fig. 63 Thailand Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 64 Latin America Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 65 Brazil country dynamics
Fig. 66 Brazil Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 67 Argentina country dynamics
Fig. 68 Argentina Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 69 MEA Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 70 South Africa country dynamics
Fig. 71 South Africa Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 72 Saudi Arabia country dynamics
Fig. 73 Saudi Arabia Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 74 UAE country dynamics
Fig. 75 UAE Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 76 Kuwait country dynamics
Fig. 77 Kuwait Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Fig. 78 Company categorization
Fig. 79 Company market position analysis
Fig. 80 Strategic framework
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Grand View Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們